Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCelltex Therapeutics Corporation
About this trial
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
Eligibility criteria
Qualifiers
Age above 18 years.
Male and female
Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures
Diagnosed as COVID-19 based upon SARS-CoV-2 RT-PCR test positive
Disqualifiers
Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start
Unwillingness or inability to comply with study procedures
Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc.
Clinically active malignant disease
Trial design
Treatments tested in this trial
- Allogeneic adipose-derived stem cells
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov